E. Paietta

发表

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.

M. Tallman, R. Ketterling, S. Luger, 2010, Blood.

Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.

D. Neuberg, M. Oken, J. Bennett, 2000, Blood.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

M. Tallman, G. Gerrard, A. Moorman, 2014 .

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

M. Tallman, G. Gerrard, A. Moorman, 2014 .

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

M. Tallman, G. Gerrard, A. Moorman, 2014 .

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

M. Tallman, G. Gerrard, A. Moorman, 2014 .

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

M. Tallman, G. Gerrard, A. Moorman, 2014 .

Investigations on karyotype evolution in patients with chronic myeloid leukemia (CML)

O. Haas, E. Paietta, E. Nacheva, 2004, Blut.

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT

L. Bullinger, R. Schlenk, H. Döhner, 2016, Bone Marrow Transplantation.

Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators

Shondra M. Pruett-Miller, M. Relling, C. Mullighan, 2023, Cell genomics.

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

Francine E. Garrett-Bakelman, M. Gönen, A. Melnick, 2023, Blood cancer journal.

Self-enforcing Feedback Activation between Bcl6 and Pre-b Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia Self-enforcing Feedback Activation between Bcl6 and Pre-b Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia Figure 1. Expressi

M. Loh, A. Melnick, R. Roeder, 2022 .

In adults with standard-risk acute lymphoblastic leukemia , the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission , and an autologous transplantation is less effective than conventional consolidation / maintenance chemotherapy in all patients

Rajiv Chopra, H. Lazarus, E. Paietta, 2008 .

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin

L. Staudt, D. Weisenburger, J. Vose, 2007 .

Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998)

J. Bennett, M. Tallman, E. Paietta, 2004, Leukemia.

Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment

Shondra M. Pruett-Miller, M. Relling, S. Kornblau, 2024, Nature communications.

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia

M. Konopleva, E. Jabbour, S. Kornblau, 2024, Cancer cell.